UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000052490
Receipt number R000059743
Scientific Title Extra ablation beyond puLmonary vein Isolation Nurtures Elimination of atrial fibrillation, or not? (Ext-LINE) Study
Date of disclosure of the study information 2023/12/01
Last modified on 2023/10/13 16:38:24

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Extra ablation beyond puLmonary vein IsolationNurtures Elimination of atrial fibrillation, or not? (Ext-LINE) Study

Acronym

Ext-LINE Study

Scientific Title

Extra ablation beyond puLmonary vein Isolation Nurtures Elimination of atrial fibrillation, or not? (Ext-LINE) Study

Scientific Title:Acronym

Ext-LINE Study

Region

Japan


Condition

Condition

Atrial fibrillation

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluated the utility of additional ExTRa mapping-guided ablation and linear ablation beyond pulmonary vein isolation for persistent atria l fibrillation in reducing recurrent tachyarrhythmias after procedure.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Atrial arrhythmia recurrence beyond 90 days after catheter ablation for atrial fibrillation

Key secondary outcomes

Cardiac function after procedure
Procedure detail (procedure time, ablation number, ablation region)
Atrial fibrillation termination rate during procedure
Adverse events
Atrial arrhythmia recurrence beyond 90 days after repeat procedures


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

No treatment

Stratification

YES

Dynamic allocation

YES

Institution consideration

Institution is considered as adjustment factor in dynamic allocation.

Blocking

YES

Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Maneuver

Interventions/Control_1

Atrial sites of high %NP (Mean %NP >35% and low voltage area <0.5mV) were ablated and ExTRa mapping-guided anatomical linear ablation was added after pulmonary vein isolation, and electrical cardiversion was performed when sinus restoration was not obtained in 15 minutes after injection of Nifekalant 0.3mg/kg

Interventions/Control_2


Interventions/Control_3

pulmonary vein isolation

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <

Age-upper limit

90 years-old >=

Gender

Male and Female

Key inclusion criteria

First time ablation procedure for persistent atri al fibrillation
Patients who can be followed for at least 1-year after procedure Patients from who we get written informed consent

Key exclusion criteria

Patients with AF termination only by pulmonary vein isolation
Patients who received ablation procedure or MAZE procedure for for atrial fi brillation before enrollment

Target sample size

180


Research contact person

Name of lead principal investigator

1st name Satoshi
Middle name
Last name Shizuta

Organization

Kyoto University Hospital

Division name

Department of Cardiovascular Medicine

Zip code

606-8507

Address

54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto

TEL

075-751-4254

Email

shizuta@kuhp.kyoto-u.ac.jp


Public contact

Name of contact person

1st name Tetsuma
Middle name
Last name Kawaji

Organization

Mitsubishi Kyoto Hospital

Division name

Department of Cardiology

Zip code

615-8087

Address

1 Katsura Gosho-cho, Nishikyo-ku, Kyoto

TEL

075-381-2111

Homepage URL


Email

kawaji@kuhp.kyoto-u.ac.jp


Sponsor or person

Institute

Kyoto University Hospital

Institute

Department

Personal name



Funding Source

Organization

Operation Cost Grant

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor

Mitsubishi Kyoto Hospital

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kyoto University Graduate School of Medicine and Faculty of Medicine, Ethics Committee

Address

54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, Kyoto, Kyoto, Kyoto

Tel

075-753-4680

Email

ethcom@kuhp.kyoto-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 12 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2023 Year 10 Month 01 Day

Date of IRB


Anticipated trial start date

2023 Year 12 Month 01 Day

Last follow-up date

2027 Year 04 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 10 Month 13 Day

Last modified on

2023 Year 10 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000059743


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name